Alexandria Chaulk, MD
Retina Specialist · Burleson, TXNPI 1275037889
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,800 of the $4,580 with a category attached, or 61.1%. Harrow Eye, LLC accounts for 65.9% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $3,812, more than ten times the $118 reported in 2022.
Across 40 payments — averaging $114.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Harrow Eye, LLC$3K
- ANI Pharmaceuticals, Inc.$383
- Alcon$266
- Regeneron Healthcare Solutions, Inc.$253
- Genentech USA, Inc.$147
- AbbVie$146
- plus $367 from 4 others
Across 10 payments — averaging $188.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2K
What the payments were for
- Consulting fees$2,80061%
- Food & beverage$1,78039%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Harrow Eye, LLC | 2 | $3,019 |
| ANI Pharmaceuticals, Inc. | 12 | $383 |
| Alcon | 3 | $266 |
| Regeneron Healthcare Solutions, Inc. | 7 | $253 |
| Genentech USA, Inc. | 2 | $147 |
| AbbVie | 6 | $146 |
| Alimera Sciences, Inc. | 5 | $132 |
| Oyster Point Pharma, Inc. | 1 | $115 |
| Regeneron | 1 | $96 |
| Sandoz | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IHEEZO$3,019
- TRIESENCE$2,800
- Constellation$146
- SUSVIMO$118
- TYRVAYA$115
How this compares
$4,580 in reported general payments places this provider in the 70th percentile of 108 retina specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 50 | $2,807 |
| MoxifloxacinMoxifloxacin Hcl | 28 | $700 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 41 | $612 |
| Ketorolac Tromethamine | 19 | $577 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 14 | $205 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Burleson
- Courtney CrawfordBurleson$342K
- Jeremiah BrownSchertz$339K
- Victor GonzalezMcAllen$335K
- Judy KimDallas$256K
- Emmanuel ChangBellaire$254K
- Ting Fang SuarezBellaire$156K
- Hemang PandyaPlano$153K
- Margaret RunnerSouthlake$71K
- Moises ChicaSan Antonio$43K
- Garvin DavisHouston$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.